Covid 19 Research using Clinical Trials (Home Page)
Powered Air purifying respiratorWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
|
Name (Synonyms) |
Correlation |
drug599 | Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic Wiki | 1.00 |
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
Highly communicable and virulent diseases, the ongoing threat of emerging infectious
diseases, and the prospect of bio-terrorism have become part of the new reality for health
care workers. SARS transmission has occurred despite the use of droplet, contact, and
airborne precautions. Potential explanations for some of the episodes of
“through-precautions” transmission include the possibility of contamination during removal of
protective clothing.
The recommended protective systems (PPS) for aerosol generating procedures set out by the US
Center for Disease Control and Prevention (CDC) and the Ontario Ministry of Health and Long
Term Care (MOHLTC) differ.
The failure of a PPS may be associated with significant consequences in terms of the
morbidity and mortality of front-line health care workers. The purpose of this study is to
determine if a difference exists between the rate of self-contamination due to deficiencies
in contact precautions for individuals wearing either the CDC or MOHLTC recommended PPS.
Study participants will don one of the two recommended PPS, be “contaminated” with an
indicator that becomes visible under ultraviolet light, and then assessed for contamination
of clothing layers and skin after removal of the PPS. They will then repeat the procedure
using the other PPS.
Primary Outcomes
Measure: The primary endpoint of this study is the presence of any detected
Measure: base clothing layer, skin, or hair contamination.
Secondary Outcomes
Measure: The secondary endpoints: 1) contamination episodes of any layer, and 2) protective
Measure: system donning and removal procedure violations
No related HPO nodes (Using clinical trials)